Current Opportunities and Future Vision of Precision Medicine in Radiation Oncology

At the 2016 American Society for Radiation Oncology annual meeting, Dr Thomas Lynch delivered a keynote address in which he presented the remarkable development of targeted therapy for non-small cell lung cancer with activating mutations in the epidermal growth factor receptor (EGFR) (1). He described the care of 1 patient, whose lung cancer had had an exceptional response to a first-generation EGFR inhibitor but that ultimately progressed, with tumor cells harboring a resistant EGFR mutation. The patient subsequently derived benefit from a next-generation EGFR inhibitor.

https://ift.tt/2HtjCeB